

KEEP CALM BUT KEEP MOVING: e-Workshop

BUSINESS CONTINUITY STRATEGIES IN EARLY CLINICAL RESEARCH DURING THE COVID-19 PANDEMIC

**ONLY 25 PLACES AVAILABLE
RESERVE YOUR SEAT TODAY**

The COVID-19 pandemic is rapidly evolving worldwide with major impacts on social life, healthcare systems and the economy. Clinical Research is confronted with a series of unprecedented challenges which must be solved rapidly and pragmatically in order to ensure business continuity.

Staff and patient safety, patient retention, and keeping up study supplies and logistics chains must all be ensured. All parties involved in management of clinical trials – Sponsors, Sites, CROs, Vendors - must act responsibly and cooperatively, having to adapt instantly to by-the-minute changes in their environments by coming up with proactive, flexible solutions while complying with GCP.

ARENSIA is inviting you to join a two-hour e-Workshop to address efficient strategies for ensuring business continuity in clinical trials in times of COVID-19 pandemic. We will share practical insights on measures already implemented at ARENSIA's Phase I Research Clinics in Eastern Europe, and look into steps to be taken by all parties of the process to ensure:

Patient: Paramount Priority

Safety, retention and enrolment

My Clinic is my Castle

Operational continuity in terms of staff, facilities, supply chain

Turn Remote to be Close

How can we switch from on-site clinic visits to home visits, use mobile pharmacy/lab services, transition to remote monitoring, etc

Keep Calm but Keep Moving

Uninterrupted preparation for new projects: regulatory and operation-wise

The e-Workshop is limited to 25 participants only, senior leaders of pharmaceutical and biotech companies worldwide. Each participant shall have the opportunity to raise questions and vividly contribute to the discussions, with the aim for all to take with them useful ideas and proven solutions to best navigate the current challenges in context of COVID-19 outbreak.

JOIN THE DISCUSSION ON THESE DATES:

THURSDAY 2ND APRIL

THURSDAY 9TH APRIL

THURSDAY 16TH APRIL

TIMES TO LOG IN:

8:00 AM PST – PACIFIC STANDARD TIME

11:00 AM EST – EASTERN STANDARD TIME

4:00 PM GMT – GREENWICH MEAN TIME

5:00 PM CET – CENTRAL EUROPEAN TIME

6:00 PM EET – EASTERN EUROPEAN TIME

FACILITATORS:

DR. CLAUDIA HESSELMANN PhD

Co-Founder & CEO

ARENSIA EXPLORATORY MEDICINE GMBH

DÜSSELDORF, GERMANY

ASSOCIATE PROF. DR. ANCA STREINU-CERCEL

MD Infectious Disease and Epidemiology, Lead Investigator

ARENSIA Phase I Research Unit

NATIONAL INSTITUTE OF INFECTIOUS DISEASES

“PROF. DR. MATEI BALS”, BUCHAREST, ROMANIA

DR. EUGENIA PROHIN

MD Clinical Pharmacology and Neurosciences,

Manager Clinical Operations ARENSIA Phase I Research Unit

“REPUBLICAN CLINICAL” HOSPITAL IN CHISINAU, MOLDOVA

ABOUT ARENSIA:

ARENSIA EXPLORATORY MEDICINE is a German operator of proprietary Research Clinics in Eastern Europe, dedicated to performing complex Phase Ib, IIa and PROOF-OF-CONCEPT clinical trials with novel molecules, involving patients across numerous disease areas. Given the outstanding patient recruitment rates achieved by ARENSIA clinics, we are able to dramatically reduce the overall number of sites, countries and recruitment periods for any early phase patient trial. Sponsors regard the recruiting speed and the data quality of ARENSIA as disruptive added value, providing them with a strategic advantage. As a testament to the excellent performance, ARENSIA is trusted by the world's largest pharmaceutical and biotechnology companies, by global CROs, as well as by venture capital funds aiming to maximize their return of investment in small/virtual biotech companies.